Aurorus / Applications / Healthcare
§ 01 / Healthcare

One measurement.
Seven healthcare frontiers.

A single non-invasive scan resolves electrophysiological activity across forty-nine channels. Same instrument, same seven-minute read — applied to seven of medicine's hardest questions.

The eight frontiers · jump to
§ 03a — § 03h
01Biomarker insight, without the blood draw 02In the clinic 03In clinical trials 04Performance optimization in sport 05Therapy evaluation and optimization 06Combat and field medicine 07Longevity and anti-aging
§ 03a
Frontier · 01
F·01Diagnostics

Biomarker insight, without the blood draw.

A single scan, pointing at what a blood panel usually requires.

Pursuing approval · validating

Routine blood panels are the backbone of modern medicine — and a friction point: phlebotomy, lab turnaround, return visits. The patients who need frequent monitoring are often the ones for whom blood draws are hardest.

In a single-center study of 193 patients, Aurorus readings showed concordance with abnormality across twelve routine inflammatory and cardiometabolic biomarkers, validated against paired venous samples. Aurorus doesn't measure these markers directly — it identifies the physiological signatures associated with them. That result opens a genuine possibility: that some of what a blood panel reveals might one day be assessed from a fingertip, without the needle.

We're candid that this is a direction, not yet a product. Blood-free biomarker assessment is what we're working toward — and validating toward clearance.

Where it changes practice
  • Concierge, longevity, and executive-physical programs — same panel, no needle
  • Serial monitoring of intervention response, where weekly retesting was previously impractical
  • Pediatric and geriatric populations
  • Any setting where the friction of phlebotomy currently limits care
Explore biomarker insight without the needle →
Important. Aurorus is not cleared for biomarker-panel use and does not replace laboratory testing. The concordance described reflects validation against paired venous samples; clearance for biomarker-panel use is actively being pursued.
§ 03b
Frontier · 02
F·02Clinical practice

In hospitals and clinics.

An objective layer beneath the standard workup.

Deployed

The hardest patients in primary and integrative practice are the ones whose lab panels return "within normal limits" — but who aren't well. Chronic fatigue, post-viral syndromes, early metabolic dysfunction, recovery from concussion, the long tail of medically-unexplained symptoms. Standard tools see what they were built to see. Everything else is left to the clinician's judgment and the patient's self-report.

Aurorus adds an objective layer beneath the standard workup. A quantitative read of physiological state across forty-nine channels — to baseline, track, and inform decisions where conventional biomarkers go quiet. FDA De Novo cleared.

Where it changes practice
  • Functional and integrative medicine practices
  • Longevity and preventive medicine programs
  • Rehabilitation and recovery monitoring
  • Patients whose presentation outruns the standard panel
Explore hospitals & clinics →
§ 03c
Frontier · 03
F·03Research instrumentation

In clinical trials.

A measurement layer for the studies that need one.

Pilot · Research partners

Aurorus makes clinical trials more robust, safer, and more cost-effective. The scan gives sponsors a clearer picture of whether a therapy is actually working — and catches safety signals earlier, before adverse effects reach clinical thresholds.

Trials reach decisions on stronger evidence, with less risk to participants and less capital spent on candidates that aren't performing.

Where it changes practice
  • Trials of integrative, lifestyle, and device interventions
  • Pre / post-intervention paired-read studies
  • Longitudinal cohorts where serial blood draws are cost-limiting
  • Decentralized trial designs
Explore research & clinical trials →
§ 03d
Frontier · 04
F·04Sport & performance

Performance optimization in sport.

Recovery, training load, and readiness — measured daily.

Pilot · Performance partners

Elite programs already know what to measure — inflammation, oxidative stress, autonomic balance, recovery state. The constraint has never been the metrics. It has been the cost and friction of capturing them frequently enough to matter.

A daily seven-minute scan removes that constraint, applied to the questions sport asks of itself: recovery, overtraining, intervention response, return-to-play.

Where it changes practice
  • Elite team and individual athletic programs
  • Training-load and recovery monitoring
  • Return-to-play assessment, particularly post-concussion (AUC 0.981 in TBI)
  • Individualized response testing for nutrition and supplementation protocols
Sports medicine in full →
§ 03e
Frontier · 05
F·05Intervention measurement

Therapy evaluation and optimization.

Before and after, on the same instrument.

Deployed

Most therapies — from oncology regimens and diabetes management to physical rehabilitation and integrative medicine — rely on a mix of lab values, imaging, and patient self-report to assess response. The data arrives slowly, captures only a narrow slice of physiological state, and often misses the changes that matter most between scheduled visits.

A scan before, a scan after — quantitative, archivable, comparable across therapies, providers, and patient populations. Clinicians see whether an intervention is working, and how the patient is changing, in the same visit it's delivered.

Where it changes practice
  • Acupuncture, manual therapy, and bodywork practices
  • Breathwork, meditation, and somatic programs
  • IV therapy, hyperbaric, and ancillary therapeutic services
  • Research comparing modalities and protocols at the field level
Read the therapy evaluation brief →
§ 03f
Frontier · 06
F·06Forward & austere care

Combat and field medicine.

Objective measurement where the lab can't reach.

Research partnerships

Forward operating bases. Disaster response. Prolonged field care. In these environments the assessment toolkit collapses to whatever can be carried, kept running without consumables, and operated by personnel who aren't phlebotomists.

Aurorus produces a quantitative read of physiological state — including the neurological and inflammatory signals field medicine most needs. The same TBI evidence (AUC 0.981) speaks directly to blast and concussive injury in operational environments.

0.981 AUC
Traumatic brain injury n = 55 (22 injured / 33 control) · blinded Blast and concussive injury assessment where subclinical TBI is often missed by current screening.
Where it changes practice
  • Triage prioritization in mass-casualty events
  • Casualty monitoring during prolonged field care and transport
  • Blast and concussive injury assessment in operational environments
  • Operator readiness and recovery in elite military programs
  • Disaster medicine and humanitarian deployments
Explore austere environments →
§ 03g
Frontier · 07
F·07Longevity & healthspan

Longevity and anti-aging.

A comprehensive baseline — and proof the protocol is working.

Deployed

Longevity medicine sells a promise: that an intervention will measurably slow decline. Its hardest problem is proof. Protocols stack supplements, peptides, hormones, and lifestyle change, and the patient — paying out of pocket, month after month — asks a fair question: is any of this actually working? Conventional markers move slowly, capture a narrow slice of physiology, and rarely produce anything the patient can see for themselves.

Aurorus establishes a comprehensive physiological baseline at intake, then re-reads it on the same instrument at every follow-up — turning a fuzzy promise into a quantitative, archivable trend. Clinicians see which interventions are moving the needle and which aren't, and can drop what isn't earning its place in the stack. The patient gets a progress evaluation they can actually read and understand — concrete evidence the program is worth their money.

Where it changes practice
  • Longevity, healthspan, and anti-aging clinics
  • A comprehensive baseline captured at intake
  • Quantifying response to supplement, peptide, and hormone protocols
  • Patient-facing progress reports that justify ongoing investment
  • Separating the interventions that work from the ones that don't
Read the longevity brief →
§ 04
Across every frontier

The capabilities that travel.

Eight applications, one instrument. The capabilities that make Aurorus useful in any of them are the same.

Capability · 01

Non-invasive.

Fingertip placement. Under seven minutes. No needles, no contrast, no preparation.

Capability · 02

Paired-read.

Built for before-and-after. Quantifies response to any intervention on the same instrument, the same patient, the same scan protocol.

Capability · 03

Quantitative output.

Forty-nine anatomically-mapped channels. Surfaced metrics. Exportable data. Designed to integrate with clinical and research workflows rather than to live in its own silo.

Capability · 04

Regulatory standing.

FDA De Novo cleared as an electrophysiological measurement system (DEN150004). The clearance authorizes the measurement, not the interpretation — which is where the application-specific work begins.

A clinician scans a child's fingertip with a portable Aurorus device at a rural village clinic
A military medic takes an Aurorus reading from a soldier in a field setting
§ 05
Evidence

What we've shown.

Aurorus is supported by one peer-reviewed publication (cardiovascular; Redox Biology, 2016) and a series of feasibility studies in preparation for publication. The headline studies are summarized below; primary sources are linked, and The Record includes the methodological discussion behind each one.

Study · 01

Traumatic brain injury

0.981AUC

Blinded feasibility study, n = 55 (22 injured / 33 control). Supports the clinical, sport-recovery, and field-medicine use cases. Foundational neurological evidence for the platform.

Blinded feasibility study · Univ. of Iowa · NCT02471625 Study record →
 Study · 02

Metabolic syndrome

0.953AUC

Single-site feasibility, n = 189. AUC 0.953 (95% CI 0.926–0.980) for syndrome status by NCEP/ATP III. Barrier-free comparison: AUC 0.951 (95% CI 0.924–0.977). Same cohort provides the biomarker concordance data shown in § 03a.

Single-site feasibility · 2023 Study record →
Aurorus is committed to publishing what these studies show and what they don't. The Record includes methodological discussion of each.
§ 06
Where this is going

Maturity, honestly.

Seven applications, at different stages of maturity. We think the honest version of that picture is more useful than a uniform one.

F · 01 Biomarker insight, without the blood draw Pursuing approval · validating
F · 02 In the clinic Deployed
F · 03 In clinical trials Pilot
F · 04 Sport & performance Pilot
F · 05 Therapy evaluation Deployed
F · 06 Combat & field medicine Research partnerships
F · 07 Longevity & anti-aging Deployed

The roadmap converges. Pilots become deployments. Research partnerships become validated programs. The instrument is the same throughout.

§ 07
For the record

What it is, and what it is not.

Healthcare is exactly where overstating a tool's reach does the most harm. We are deliberate about Aurorus's role inside a clinical workflow.

For the record · placed deliberately FDA De Novo · DEN150004
Aurorus is
  • An FDA De Novo cleared (DEN150004) electrophysiological measurement tool that provides quantitative data on electrophysiological and related bioelectric signals.
  • A general wellness and research tool that offers insights into an individual’s physiological and autonomic state.
  • A fast, non-invasive way to track changes over time in response to wellness practices, lifestyle interventions, and other therapies.
  • A complementary technology designed to support practitioners in functional and integrative settings.
Aurorus is not
  • A diagnostic device for any specific disease or medical condition.
  • A replacement for conventional medical diagnostics, imaging (MRI, CT), or clinical laboratory testing.
  • Immune to all biological variability — factors such as age, medications, recent meals, and acute states can influence readings and must be considered in context.
  • Intended to diagnose, treat, cure, or prevent any disease.
  • A standalone clinical decision-making tool — results should always be interpreted by qualified practitioners alongside other clinical findings.
§ 08
Next steps

Where should we start?

Tell us who you are. We'll route the conversation to the right person.

Route · 01
Clinician or practice

For functional, integrative, longevity, and rehabilitation programs evaluating the platform.

Discovery call → Route · 02
Researcher or trial sponsor

For investigators and sponsors considering Aurorus as a study endpoint or instrument.

Research partnership → Route · 03
Performance program

For elite team programs, sports medicine groups, and individual performance practices.

Program inquiry → Route · 04
Field, military, or government

For operational medicine, forward care, disaster response, and military readiness programs.

Program inquiry → Route · 05
Investor or media

For capital, press, and general inquiries about the company and its programs.

Contact →

Aurorus is an electrophysiological measurement system cleared by the FDA under De Novo classification (DEN150004). It is not an in-vitro diagnostic and does not replace clinical judgment or laboratory testing where required.